Mark Wildgust, Vice President of Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on X:
“A targeted dual-protein lock. A completely new way of thinking about cancer therapy.
JNJ6143 is a first-in-class RIPTAC™ oral small molecule designed to selectively bring together two proteins – AR and BRD4 – inside prostate cancer cells, creating a ternary complex that disrupts cancer-driving biology and triggers tumor cell death.
Benjamin Garmezy showcased this at ESMO2026 today and it has been the talk of the meeting!”
You can also read:
DASL-HiCaP at ESMO 2026: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer
